Invasight develops first-in-class, protein-protein interaction inhibitors against invasive cancers. Our breakthrough technology, ACINDA accelerates drug discovery and enables precise design of small molecule inhibitors against specific proteins, which cause cancer cell invasion.
Products, services, technology
Our most advanced, first-in-class, protein-protein interaction inhibitor is F2i, an inhibitor of pro-invasive FGFR signalling. F2i is currently in 'pre-clinical' validation stage of drug development.
Strategic partnerships, joint development, integrated drug discovery